Publications by authors named "Francesco Nuzzo"

Claim this Profile
C
CAR-T cell therapy for breast cancer: Current status and future perspective.
Giuseppe Buono, Monica Capozzi, Roberta Caputo, Vincenzo Di Lauro, Daniela Cianniello, Francesco Nuzzo

Cancer Treat Rev· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study.
Caterina Caminiti, Giuseppe Maglietta, Laura Arenare, Raimondo Di Liello, Gessica Migliaccio, Francesco Nuzzo

Breast· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis.
Roberta Caputo, Giuseppe Buono, Michela Piezzo, Claudia Martinelli, Daniela Cianniello, Francesco Nuzzo

Front Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion.
Roberta Caputo, Giuseppe Buono, Vincenzo Di Lauro, Daniela Cianniello, Claudia Von Arx, Francesco Nuzzo

Future Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Overview of the Roles of CDK4/6 Inhibitors in Metastatic Breast Cancer Elderly Patients.
Carmen Pacilio, Gerardo Rosati, Anna Crispo, Sabrina Bimonte, Francesca DI Rella, Francesco Nuzzo

In Vivo· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice.
Giuseppe Buono, Grazia Arpino, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Francesco Nuzzo

Front Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Michela Piezzo, Paolo Chiodini, Maria Riemma, Stefania Cocco, Roberta Caputo, Francesco Nuzzo

Int J Mol Sci· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
Michela Piezzo, Stefania Cocco, Roberta Caputo, Daniela Cianniello, Germira Di Gioia, Francesco Nuzzo

Int J Mol Sci· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
Francesco Perrone, Michelino De Laurentiis, Sabino De Placido, Michele Orditura, Saverio Cinieri, Francesco Nuzzo

Eur J Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety.
Ferdinando Riccardi, Giuseppe Colantuoni, Anna Diana, Carmela Mocerino, Giacomo Cartenì, Francesco Nuzzo

Mol Clin Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, Giancarlo Bisagni, Grazia Arpino, Francesco Nuzzo

Lancet Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Daniele Generali, Filippo Montemurro, Roberto Bordonaro, Antonino Mafodda, Sante Romito, Francesco Nuzzo

Oncologist· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer.
Francesca Collina, Maurizio Di Bonito, Valeria Li Bergolis, Michelino De Laurentiis, Carlo Vitagliano, Francesco Nuzzo

Biomed Res Int· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.
Massimo Di Maio, Ciro Gallo, Natasha B Leighl, Maria Carmela Piccirillo, Gennaro Daniele, Francesco Nuzzo

J Clin Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Francesco Nuzzo, Alessandro Morabito, Adriano Gravina, Francesca Di Rella, Gabriella Landi

BMC Cancer· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.
Emanuela Rossi, Alessandro Morabito, Francesca Di Rella, Giuseppe Esposito, Adriano Gravina, Francesco Nuzzo

J Clin Oncol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
Francesco Nuzzo, Alessandro Morabito, Ermelinda De Maio, Francesca Di Rella, Adriano Gravina

Crit Rev Oncol Hematol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
Emanuela Rossi, Alessandro Morabito, Ermelinda De Maio, Francesca Di Rella, Giuseppe Esposito, Francesco Nuzzo

J Clin Oncol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment.
Alessandro Morabito, Maria Carmela Piccirillo, Katia Monaco, Carmen Pacilio, Francesco Nuzzo

Oncologist· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
Ermelinda De Maio, Carmen Pacilio, Adriano Gravina, Alessandro Morabito, Francesca Di Rella, Francesco Nuzzo

BMC Cancer· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience.
Ermelinda De Maio, Adriano Gravina, Carmen Pacilio, Gerardo Amabile, Vincenzo Labonia, Francesco Nuzzo

BMC Cancer· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? a single-center phase 2 study.
Emanuela Rossi, Francesco Perrone, Vincenzo Labonia, Gabriella Landi, Francesco Nuzzo

Oncology· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
Alfredo Berruti, Raffaella Bitossi, Gabriella Gorzegno, Alberto Bottini, Palmiro Alquati, Francesco Nuzzo

J Clin Oncol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study.
Andrea de Matteis, Francesco Nuzzo, Giuseppe D'Aiuto, Vincenzo Labonia, Gabriella Landi

Cancer· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis